Bristol-myers Squibb Stock Fair Value – Bristol-Myers Squibb Expands Oncology Portfolio with Acquisition of Rayzebio for $4.1B
December 27, 2023
☀️Trending News
BRISTOL-MYERS ($NYSE:BMY): Bristol-Myers Squibb is a global biopharmaceutical company that focuses on developing and delivering innovative medicines to patients worldwide. In a move to strengthen its presence in the oncology market, the company announced its acquisition of Rayzebio for $4.1 billion. Rayzebio’s radiopharmaceutical platform is expected to enhance Bristol-Myers Squibb’s already impressive oncology portfolio. This acquisition will bring Rayzebio’s innovative radiopharmaceuticals, such as their lead product, a therapy for prostate cancer, into Bristol-Myers Squibb’s product pipeline. This will not only increase the company’s oncology portfolio significantly, but it will also help them to expand geographically.
It is anticipated that the new products will be available in multiple countries and provide a greater reach for Bristol-Myers Squibb as they strive to meet the increasing demand for oncology treatments around the world. The acquisition of Rayzebio marks a major step forward for Bristol-Myers Squibb as they continue to invest in growing their oncology portfolio. It is expected that the combination of Rayzebio’s radiopharmaceutical platform with Bristol-Myers Squibb’s existing portfolio of products will enable the company to better serve patients in need of oncology treatments. With this acquisition, Bristol-Myers Squibb is sure to remain a leader in the global oncology market.
Market Price
This acquisition significantly expands BRISTOL-MYERS SQUIBB‘s oncology portfolio, and will give them access to Rayzebio’s pipeline of cancer drugs. On the same day, BRISTOL-MYERS SQUIBB stock opened at $52.4 and closed at $51.4, down by 1.6% from the previous closing price of $52.3. This acquisition shows that BRISTOL-MYERS SQUIBB is committed to developing innovative treatments for cancer and other diseases. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…
| Total Revenues | Net Income | Net Margin |
| 44.94k | 8.29k | 19.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…
| Operations | Investing | Financing |
| 12.91k | 264 | -13.63k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 91.26k | 62.2k | 14.25 |
Key Ratios Snapshot
Some of the financial key ratios for Bristol-myers Squibb are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.5% | 30.7% | 21.7% |
| FCF Margin | ROE | ROA |
| 26.0% | 20.0% | 6.7% |
Analysis – Bristol-myers Squibb Stock Fair Value
At GoodWhale, our mission is to help investors make informed and confident decisions about their portfolio. That is why we have taken a deep dive into the financials of BRISTOL-MYERS SQUIBB. After analyzing the information available, we have concluded that the intrinsic value of BRISTOL-MYERS SQUIBB shares is around $68.9, as calculated by our proprietary Valuation Line. Currently, BRISTOL-MYERS SQUIBB stock is trading at $51.4, which means it is undervalued by 25.4%. Therefore, at GoodWhale, we believe that now could be a great time to invest in BRISTOL-MYERS SQUIBB stock. More…
Peers
The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.
– Amgen Inc ($NASDAQ:AMGN)
Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.
Summary
Bristol-Myers Squibb (BMY) is a leading biopharmaceutical company and recently made a strategic move to acquire the radiopharmaceutical platform of Rayzebio in a $4.1 billion deal. This acquisition is expected to add a major oncology portfolio to their existing line of products and services. Investors should keep a close eye on this news as the acquisition may likely result in higher stock prices and better returns for shareholders due to the potential for increased revenue streams.
Moreover, the company appears to be well-positioned to benefit from the expected growth in the radiopharmaceutical market. Therefore, it is likely a good time to consider investing in Bristol-Myers Squibb.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
